EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Influencing and Prognostic Factors of End-Stage Hypertrophic Cardiomyopathy

Yisen Zhang iD, Wenhui Xie, Yaqing Dai, Zefeng Wu, Yuping Lin, Ming Yang, Huashan Hong

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.15010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Yisen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Fujian Key Laboratory of Vascular Aging (Fujian Medical University), Fujian Institute of Geriatrics, Fujian Heart Dise…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Programs, Fujian Province Key Clinical Specialty Discipline Construction Program, National Key Clinical Specialty Discipline Construction Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

End-stage hypertrophic cardiomyopathy (ES-HCM) is a disease with severe complications and a poor prognosis. This study aimed to explore the influencing and prognostic factors of ES-HCM. Methods and results A total of 1282 patients with HCM who were hospitalized for the first time at Fujian Medical University Union Hospital between 1 January 2013 and 30 September 2021 were recorded. The patients with HCM and left ventricular ejection fraction (LVEF) < 50% were defined as having ES-HCM, and a control group (LVEF ≥ 50%) was generated from the collected medical records of HCM. The patients were matched in a ratio of 4:1 based on age and sex. Logistic regression analysis was used to determine the influencing factors of ES-HCM. Kaplan–Meier survival analysis was performed to analyse the clinical outcomes of ES-HCM patients. A total of 250 inpatients with HCM were enrolled in the study; 50 patients had ES-HCM, and 200 had HCM with LVEF ≥ 50%. The mean age of the patients at enrolment was 62.5 ± 10.3 years, and 215 patients (215/250, 86.0%) were male. The median follow-up time of the patients was 2.8 (1.4–5.4) years. The incidence of all-cause death and cardiovascular death in patients with ES-HCM was higher than those in patients with HCM and LVEF ≥ 50% (22/50 [44.0%] vs. 13/200 [6.5%]; 12/50 [24.0%] vs. 4/200 [2.0%], all P < 0.001). Multivariate logistic regression analysis showed that the influencing factors associated with ES-HCM included age at first symptom onset (odds ratio [OR] = 0.95, 95% CI [0.90, 1.00], P = 0.042), New York Heart Association (NYHA) class (OR = 7.73, 95% CI [2.93, 20.41], P < 0.001), heart rate (OR = 1.07, 95% CI [1.02, 1.12], P = 0.003), QRS duration (OR = 1.03, 95% CI [1.00, 1.05], P = 0.020), left ventricular end-diastolic diameter (LVEDD) (OR = 1.15, 95% CI [1.04, 1.28], P = 0.006), left atrial anteroposterior diameter (LAD) (OR = 1.13, 95% CI [1.03, 1.24], P = 0.012), and maximum left ventricular wall thickness (MLVWT) (OR = 0.80, 95% CI [0.68, 0.93], P = 0.005). Among the 50 patients with ES-HCM, NYHA class (P < 0.001) and heart rate (P = 0.017) were each associated with a higher likelihood and earlier occurrence of heart transplantation or all-cause mortality in univariate analyses.

Conclusions

The influencing factors for ES-HCM included the age at first symptom onset, NYHA class, heart rate, QRS duration, LVEDD, LAD, and MLVWT. Both NYHA class and heart rate were related to the prognosis of ES-HCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicStroke VolumeVentricular Function, LeftHumansMaleFemaleMiddle AgedPrognosisRetrospective StudiesFollow-Up StudiesSurvival RateChinaRisk FactorsAgedIncidence

Stichwörter der Autor:innen

DeathEnd‐stage phaseHeart transplantationHypertrophic cardiomyopathy

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Fujian Key Laboratory of Vascular Aging (Fujian Medical University), Fujian Institute of Geriatrics, Fujian Heart Disease Center, Fujian Medical University Union Hospital, Fuzhou, China.
  • Department of Geriatrics, Department of Cardiology, Fujian Key Laboratory of Vascular Aging (Fujian Medical University), Fujian Institute of Geriatrics, Fujian Heart Disease Center, Fujian Clinical Research Center for S…

ORCID-Profile: Yisen Zhang

Förderung

  • National Key Clinical Specialty Discipline Construction Programs
  • Fujian Province Key Clinical Specialty Discipline Construction Program
  • National Key Clinical Specialty Discipline Construction Program of China

Zitieren

APA

Zhang, Y., Xie, W., Dai, Y., Wu, Z., Lin, Y., Yang, M., & Hong, H. (2024). Influencing and Prognostic Factors of End-Stage Hypertrophic Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15010

Vancouver

Zhang Y, Xie W, Dai Y, Wu Z, Lin Y, Yang M, et al. Influencing and Prognostic Factors of End-Stage Hypertrophic Cardiomyopathy. ESC Heart Failure. 2024. doi:10.1002/ehf2.15010

BibTeX
@article{Zhang2024,
  author = {Zhang, Yisen and Xie, Wenhui and Dai, Yaqing and Wu, Zefeng and Lin, Yuping and Yang, Ming and Hong, Huashan},
  title = {Influencing and Prognostic Factors of End-Stage Hypertrophic Cardiomyopathy},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.15010}
}
Kostenlos starten →